Isatin (indol-2,3-dione) is an endogenous indole found in the brain, peripheral tissues and biological body fluids of humans and animals. Its wide spectrum of biological activity is realized via interaction with numerous isatin-binding proteins; these include proteins playing an important role in the development of neurodegenerative pathology. In the context of the neuroprotective effect, the effect of isatin is comparable to the effects of deprenyl, a pharmacological agent used for treatment of Parkinson's disease. In this study, the effects of the course of deprenyl (1 mg/kg) and isatin (20 mg/kg) administration for 21 days on the profile of the isatin-binding proteins of the liver of mice have been investigated. Proteomic profiling of liver isatin-binding proteins of control mice by means of 5-aminocaproylisatin as an affinity ligand resulted in identification of 105 proteins. Treatment of animals with a low dose of isatin slightly decreased (up to 91), while injections of deprenyl slightly increased (up to 120) the total number of isatin-binding proteins. 75 proteins were common for all three groups; they represented from 62.5% (in deprenyl treated mice) and 71% (in control mice), to 82% (isatin treated mice) of the total number of identified liver isatin-binding proteins. Proteomic analysis of the isatin-binding proteins of mice treated with isatin (20 mg/kg) or deprenyl (1 mg/kg) for 21 days revealed a representative group of proteins (n=30) that were sensitive to the administration of these substances. Taking into account the previously obtained results, it is reasonable to suggest that the change in the profile of isatin-binding proteins may be attributed to accumulation of isatin and deprenyl in the liver and interaction with target proteins prevents their subsequent binding to the affinity sorbent. In this context, the identified isatin-binding liver proteins of control animals that do not bind to the affinity sorbent (immobilized isatin analogue) after treatment of animals with either deprenyl or isatin appear to be specific targets directly interacting with isatin in vivo.
Buneeva O.A., Kopylov A.T., Zgoda V.G., Medvedev A.E. (2018) The effect of deprenyl and isatin administration to mice on the proteomic profile of liver isatin-binding proteins. Biomeditsinskaya Khimiya, 64(4), 354-359.
Buneeva O.A. et al. The effect of deprenyl and isatin administration to mice on the proteomic profile of liver isatin-binding proteins // Biomeditsinskaya Khimiya. - 2018. - V. 64. -N 4. - P. 354-359.
Buneeva O.A. et al., "The effect of deprenyl and isatin administration to mice on the proteomic profile of liver isatin-binding proteins." Biomeditsinskaya Khimiya 64.4 (2018): 354-359.
Buneeva, O. A., Kopylov, A. T., Zgoda, V. G., Medvedev, A. E. (2018). The effect of deprenyl and isatin administration to mice on the proteomic profile of liver isatin-binding proteins. Biomeditsinskaya Khimiya, 64(4), 354-359.
Crumeyrolle-Arias M., Buneeva O., Zgoda V., Kopylov A., Cardona A., Tournaire M.-C., Pozdnev V., Glover V., Medvedev A. (2009) J. Neurosci. Res., 87, 2763-2772. CrossRef Scholar google search
Buneeva O., Gnedenko O., Zgoda V., Kopylov A., Glover V., Ivanov A., Medvedev A., Archakov A. (2010) Proteomics, 10, 23-37. CrossRef Scholar google search
Kragten E., Lalande I., Zimmermann K., Roggo S., Schindler P., Muller D., van Oostrum J., Waldmeier P., Furst P. (1998) J. Biol. Chem., 273, 5821-5828. CrossRef Scholar google search
Hara A., Endo S., Matsunaga T., El-Kabbani O., Miura T., Nishinaka T., Terada T. (2017) Biochem. Pharmacol., 138, 185-192. CrossRef Scholar google search
Huang W., Ding L., Huang Q., Hu H., Liu S., Yang X., Hu X., Dang Y., Shen S., Li J., Ji X., Jiang S., Liu J.O., Yu L. (2010) Hepatology, 52, 703-714. CrossRef Scholar google search
